• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Neurology

COPD associated with increased risk for nonamnestic-mild cognitive impairment

byAnees DaudandJames Jiang
March 18, 2014
in Neurology, Pulmonology
Reading Time: 3 mins read
Dual PDE3/PDE4 inhibitor may be effective treatment for asthma and COPD
Share on FacebookShare on Twitter

Image: PD 

1. In a population based study of older adults, COPD was associated with an almost two-fold increased risk for nonamnestic-mild cognitive impairment (NA-MCI). 

2. The relationship between COPD and MCI appeared to be dose-dependent, wherein a longer duration of COPD was associated with a greater risk for MCI. 

Evidence Rating Level: 2 (Good)

Study Rundown: COPD causes a state of hypoxemia and hypercapnia. Previous studies have suggested that this may result in mild cognitive impairment (MCI), which can progress to dementia. This study was conducted to further characterize the relationship between COPD and MCI. Participants were chosen from Mayo Clinic Study of Aging (MCSA). The results suggested that COPD was associated with an almost two-fold increased risk for NA-MCI. There appeared to be a dose-response relationship that suggested that duration of COPD longer than five years had a greater risk for NA-MCI.

The strength of this study was the population based cohort of participants and the thorough battery of tests used to determine the cognitive status of the participants. They also accounted for a large number of co-morbidities and other confounding variables in the statistical analysis to isolate COPD as an independent risk factor for MCI. However, there were several weaknesses as well. The study population was mostly Caucasian and of Northern European ancestry, limiting its generalizability. In addition, the diagnosis of COPD was based on medical providers’ comments or medication prescriptions rather than from spirometry results. The hazard ratio confidence intervals were wide, suggesting the study may have been somewhat underpowered.

RELATED REPORTS

Artificial intelligence decision support software improved spirometry diagnosis performance in primary care

GSK and Hengrui Pharma Forge $500 Million China Collaboration, Including PDE3/4 Inhibitors

2 Minute Medicine: Pharma Roundup – Landmark lung approval, billion-dollar obesity drug deal, oncology safety halt, and GSK’s China push [August 14 2025]

Click to read the study, published today in JAMA Neurology

Relevant Reading: Chronic obstructive pulmonary disease and asthma and the risk of mild cognitive impairment and dementia: a population based CAIDE study

In-Depth [prospective cohort study]: This study consisted of 1,425 cognitively normal adults in the age range 70-89yrs. They were chosen from the Mayo Clinic Study of Aging (MCSA) cohort from Olmsted County, Minnesota with a mean follow up period of 5.1yrs. The cognitive status of the participants was determined by a composite score of Clinical Dementia Rating Scale, Short Test of Mental Status, Unified Parkinson’s Disease Rating Scale, and a neuropsychological battery test, along with consensus agreement between testers. Diagnosis and duration of COPD was determined from medical records.

Out of total participants, 370 developed MCI, of which 97 (26.2%) had NA-MCI. At baseline, 171 participants had a diagnosis of COPD. After using the statistical model that accounted for the most number of confounding variables, COPD was associated with an increased risk for NA-MCI (HR 1.83; 95% CI, 1.04-3.23). There was no statistically significant association between COPD and other subtypes of MCI. Furthermore, there was a dose-response relationship between the duration of COPD and NA-MCI, in which there was a greater risk for NA-MCI if the duration of COPD was longer than 5yrs (HR 2.58; 95% CI, 1.32-5.06) compared to duration fewer than 5yrs (HR 1.14; 95% CI, 0.46-2.79).

More from this author: Acetaminophen use during pregnancy associated with increased ADHD-like problems in children, Added sugar intake associated with mortality from cardiovascular disease, Warfarin, antibiotic interactions may not be clinically significant in ambulatory setting, Alcohol consumption inversely related to risk of developing Multiple Sclerosis , Peripregnancy nut consumption may decrease development of nut allergies

 ©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: copd
Previous Post

HIV infection may increase rate of HCV-related hepatic decompensation

Next Post

Estimated three quarters of people with influenza are asymptomatic [Flu Watch study]

RelatedReports

Combination salmeterol-fluticasone therapy noninferior to fluticasone monotherapy for asthma events: The VESTRI trial
Artificial Intelligence

Artificial intelligence decision support software improved spirometry diagnosis performance in primary care

May 12, 2026
HOSPITAL score predicts risk of 30-day potentially avoidable readmission to hospital
Pharma

GSK and Hengrui Pharma Forge $500 Million China Collaboration, Including PDE3/4 Inhibitors

August 27, 2025
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Pharma

2 Minute Medicine: Pharma Roundup – Landmark lung approval, billion-dollar obesity drug deal, oncology safety halt, and GSK’s China push [August 14 2025]

August 14, 2025
2 Minute Medicine Rewind May 20, 2019
Chronic Disease

Mepolizumab decreases exacerbations in patients with eosinophilic COPD

May 20, 2025
Next Post
Influenza vaccine associated with lower risk of major cardiovascular events

Estimated three quarters of people with influenza are asymptomatic [Flu Watch study]

Higher omega-3 blood levels associated with larger brain volumes

Omega Fatty Acids and Lutein + Zeaxanthin did not improve cardiovascular outcomes

Lower target oxygen saturation in extremely preterm infants appears safe

Age-adjusted D-dimer levels may rule out pulmonary embolism [ADJUST-PE trial]

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Deficits in executive function are not universal among patients with alcohol use disorder
  • Choice of bicarbonate-buffered solution versus compound sodium lactate as the intraoperative crystalloid solution during abdominal surgery remains unclear
  • Artificial intelligence (AI)-based coronary calcium quantification successfully identified patients who could benefit from lipid-lowering therapy
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.